Formation Bio is rewriting the rules of drug development at a time when AI is accelerating drug discovery far faster than the industry can bring new therapies to patients. CEO Ben Liu goes Inside the ICE House to explain why the real bottleneck in pharma isn't finding promising drug candidates, it's developing them efficiently and at scale. He unpacks Formation Bio's AI-native model, which acquires already-discovered drugs and deploys proprietary tools to optimize trial design, predict clinical outcomes, and identify overlooked disease indications.